Atezolizumab and Bevacizumab in Therapy for Patients with Hepatocellular Carcinoma in Real Clinical Practice

   Randomized clinical trials and actual clinical practice differsignificantly. Evidence-based medicine develops new agents referring to, primarily, pharmaceutical findings, preclinical studies and, most importantly, randomized clinical trials. Hepatocellular carcinoma is the most common primary malignancy of the liver, and one of the main causes of fatal outcomes among cancer patients worldwide, including in the Asia-Pacific region, with an estimated 800,000 deaths annually. For more than 10 years, sorafenib, a tyrosine kinase inhibitor, was the only authorized treatment for advanced hepatocellular carcinoma. The next stage in the development of drug therapy for hepatocellular carcinoma involved immune checkpoint inhibitors. The combination of atezolizumab with bevacizumab in the phase III trial (IMbrave150) improved outcomes of advanced hepatocellular carcinoma, such as overall survival and progression-free survival (6.8 versus 4.3). The paper presents the trials of atezolizumab and bevacizumab combination, demonstrates comparable data on the treatment of patients with HCC in real clinical practice and data on the phase III IMbrave150. To further analyze the efficacy of the combination of atezolizumab and bevacizumab, prospective clinical trials should include heterogeneous patient groups.

1. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019; 380 (15): 1450–62. DOI: 10.1056/NEJMra1713263

2. Akhmetgaeeva K. T., Lipatov O. N., Menshikov K. V., Sultanbaev A. V. The incidence of primary liver cancer in the Republic of Bashkortostan. In: Belye nochi 2020: Abstracts of the VI St. Petersburg International Cancer Forum. St. Petersburg; 2020. P. 22 (In Russ.).

3. Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol. 2017; 1018: 11–21. DOI: 10.1007/978-981-10-5765-6_2

4. Kanwal F., Kramer J. R., Mapakshi S., Natarajan Y., Chayanupatkul M., Richardson P. A., et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018; 155 (6): 1828–37.e2. DOI: 10.1053/j.gastro.2018.08.024

5. Menshikov K. V., Sultanbaev A. V., Musin S. I., Rakhmatullina I. R., Menshikova I. A., Abdeev R. R., et al. Hepatocellular carcinoma: aetiology and mechanisms of development. A literature review. Creative surgery and oncology. 2022; 12 (2): 139–50 (In Russ.). DOI: 10.24060/2076-3093-2022-12-2-139-150

6. Llovet J. M., Villanueva A., Lachenmayer A., Finn R. S. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015; 12 (7): 408–24. DOI: 10.1038/nrclinonc.2015.103

7. Cheng A. L., Kang Y. K., Chen Z., Tsao C. J., Qin S., Kim J. S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009; 10 (1): 25–34. DOI: 10.1016/S1470-2045(08)70285-7

8. Llovet J. M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J. F., et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359 (4): 378–90. DOI: 10.1056/NEJMoa0708857

9. Menshikov K. V., Sultanbaev A. V., Musin S. I., Menshikova I. A., Abdeev R. R., Sultanbaeva N. I., et al. Immunotherapy of advanced hepatocellular carcinoma: case report and literature review. Meditsinskiy sovet = Medical Council. 2022; (9): 31–9 (In Russ.). DOI: 10.21518/2079-701X-2022-16-9-31-39.

10. Kudo M., Finn R. S., Qin S., Han K. H., Ikeda K., Piscaglia F., et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391 (10126): 1163–73. DOI: 10.1016/S0140-6736(18)30207-1

11. Bruix J., Qin S., Merle P., Granito A., Huang Y. H., Bodoky G., et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389 (10064): 56–66. DOI: 10.1016/S0140-6736(16)32453-9

12. Menshikov K. V., Sultanbaev A. V., Akhmetgareeva K. T., Lipatov D. O. Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review. Journal of Modern Oncology. 2021; 23 (1): 156-161. (In Russ.) DOI: 10.26442/18151434.2021.1.200785.

13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69 (1): 182–236. DOI: 10.1016/j.jhep.2018.03.019

14. Heimbach J. K., Kulik L. M., Finn R. S., Sirlin C. B., Abecassis M. M., Roberts L. R., et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67 (1): 358–80. DOI: 10.1002/hep.29086

15. Matsui J., Yamamoto Y., Funahashi Y., Tsuruoka A., Watanabe T., Wakabayashi T., et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008; 122 (3): 664–71. DOI: 10.1002/ijc.23131

16. Tamai T., Hayato S., Hojo S., Suzuki T., Okusaka T., Ikeda K., et al. Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 2017; 57 (9): 1138–47. DOI: 10.1002/jcph.917

17. Finn R. S., Ikeda M., Zhu A. X., Sung M. W., Baron A. D., Kudo M., et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020; 38 (26): 2960–70. DOI: 10.1200/JCO.20.00808

18. Pishvaian M. J., Lee M. S., Ryoo B.-Y., Stein S., Lee K-H., Verret W., et al. Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol. 2018; 29 (Suppl.8): 718–9.

19. Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382 (20): 1894–905. DOI: 10.1056/NEJMoa1915745

20. Giannini E. G., Aglitti A., Borzio M., Gambato M., Guarino M., Iavarone M., et al. Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and The ITA.LI.CA Cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers (Basel). 2019;11(11):1689. DOI: 10.3390/cancers11111689

21. Gordan J. D., Kennedy E. B., Abou-Alfa G. K., Beg M. S., Brower S. T., Gade T. P., et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38 (36): 4317–45. DOI: 10.1200/JCO.20.02672

22. de Castro T., Jochheim L. S., Bathon M., Welland S., Scheiner B., Shmanko K., et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022; 14: 17588359221080298. DOI: 10.1177/17588359221080298

23. Hatanaka T., Kakizaki S., Hiraoka A., Tada T., Hirooka M., Kariyama K., et al. Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study. Cancer Med. 2023; 12 (5): 5293–303. DOI: 10.1002/cam4.5337

24. Shimose S., Hiraoka A., Nakano M., Iwamoto H., Tanaka M., Tanaka T., et al. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Med. 2021; 10 (23): 8530–41. DOI: 10.1002/cam4.4367

25. Hatanaka T., Kakizaki S., Nagashima T., Namikawa M., Ueno T., Tojima H., et al. Lenvatinib for hepatocellular carcinoma patients with nonviral infection who were unlikely to respond to immunotherapy: a retrospective, comparative study. Oncology. 2021; 99 (10): 641–51. DOI: 10.1159/000517494

26. Tsuchiya K., Kurosaki M., Sakamoto A., Marusawa H., Kojima Y., Hasebe C., et al. The real-world data in japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers (Basel). 2021; 13 (11): 2608. DOI: 10.3390/cancers13112608

27. Hiraoka A., Kumada T., Tada T., Tani J., Kariyama K., Fukunishi S., et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep. 2021; 11 (1): 16663. DOI: 10.1038/s41598-021-96089-x

28. Tomonari T., Sato Y., Tanaka H., Mitsuhashi T., Hirao A., Tanaka T., et al. Th erapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open. 2021; 5 (11): 1275–83. DOI: 10.1002/jgh3.12663

29. Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60 (8): 646–9. DOI: 10.1002/bjs.1800600817

30. Tada T., Kumada T., Hiraoka A., Hirooka M., Kariyama K., Tani J., et al. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Med. 2022; 11 (20): 3796–808. DOI: 10.1002/cam4.4763

31. Singal A. G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72 (2): 250–61. DOI: 10.1016/j.jhep.2019.08.025

32. Global Burden of Disease Liver Cancer Collaboration; Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M. A., Allen C., et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017; 3 (12): 1683–91. DOI: 10.1001/jamaoncol.2017.3055

33. 33 Kumada T., Toyoda H., Tada T., Yasuda S., Tanaka J. Changes in background liver function in patients with hepatocellular carcinoma over 30 years: comparison of child-pugh classification and albumin bilirubin grade. Liver Cancer. 2020; 9 (5): 518–28. DOI: 10.1159/000507933

34. Johnson P. J., Berhane S., Kagebayashi C., Satomura S., Teng M., Reeves H. L., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33 (6): 550–8. DOI: 10.1200/JCO.2014.57.9151

35. Iwamoto H., Shimose S., Noda Y., Shirono T., Niizeki T., Nakano M., et al. Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice. Cancers (Basel). 2021; 13 (11): 2786. DOI: 10.3390/cancers13112786

36. 36 Finn R. S., Ryoo B. Y., Merle P., Kudo M., Bouattour M., Lim H. Y., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020; 38 (3): 193–202. DOI: 10.1200/JCO.19.01307

37. Yau T., Park J. W., Finn R. S., Cheng A. L., Mathurin P., Edeline J., et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022; 23 (1): 77–90. DOI: 10.1016/S1470-2045(21)00604-5

38. Cheng A. L., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76 (4): 862–73. DOI: 10.1016/j.jhep.2021.11.030

39. Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T.-Y., et al. IMbrave150: Updated Overall Survival (OS) Data from a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) versus Sorafenib (Sor) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC). J Clin Oncol. 2021; 39 (3S): 267. DOI: 10.1200/JCO.2021.39.3_suppl.267

40. Galle P. R., Finn R. S., Qin S., Ikeda M., Zhu A. X., Kim T. Y., et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22 (7): 991–1001. DOI: 10.1016/S1470-2045(21)00151-0

41. Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45 (2): 228–47. DOI: 10.1016/j.ejca.2008.10.026

42. 42 Lencioni R., Llovet J. M. Modifi ed RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30 (1): 52–60. DOI: 10.1055/s-0030-1247132

43. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Bethesda; 2009.

44. Common Terminology Criteria for Adverse Events (CTCAE). v.5.0; Cancer Therapy Evaluation Program (CTEP). Rockville; 2017.

45. Himmelsbach V., Pinter M., Scheiner B., Venerito M., Sinner F., Zimpel C., et al. Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers. Cancers (Basel). 2022; 14 (7): 1722. DOI: 10.3390/cancers14071722

46. Qin S., Ren Z., Feng Y. H., Yau T., Wang B., Zhao H., et al. Atezolizumab plus bevacizumab versus sorafenib in the chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. Liver Cancer. 2021; 10 (4): 296–308. DOI: 10.1159/000513486

47. Pfister D., Núñez N. G., Pinyol R., Govaere O., Pinter M., Szydlowska M., et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; 592 (7854): 450–6. DOI: 10.1038/s41586-021-03362-0

48. Inada Y., Mizukoshi E., Seike T., Tamai T., Iida N., Kitahara M., et al. Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology. 2019; 69 (2): 653–65. DOI: 10.1002/hep.30212